Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
20 Januar 2022 - 1:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2022.
Commission File Number: 001-39071
ADC Therapeutics SA
(Exact name of registrant as specified in its
charter)
Biopôle
Route de la Corniche 3B
1066 Epalinges
Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
ADC Therapeutics SA
|
Date: January 20, 2022
|
|
|
|
|
By:
|
/s/ Michael Forer
|
|
Name:
|
Michael Forer
|
|
Title:
|
Executive Vice President & General Counsel
|
EXHIBIT INDEX
Exhibit No.
|
Description
|
99.1
|
Press release dated January 20, 2022
|
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024